The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models

GY Ho; CJ Vandenberg; R Lim; EL Christie; DW Garsed; E Lieschke; K Nesic; O Kondrashova; G Ratnayake; M Radke; JS Penington; A Carmagnac; V Heong; EL Kyran; F Zhang; N Traficante; R Huang; A Dobrovic; EM Swisher; O McNally; D Kee; MJ Wakefield; AT Papenfuss; DDL Bowtell; HE Barker; CL Scott

Journal article

The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models

GY Ho, CJ Vandenberg, R Lim, EL Christie, DW Garsed, E Lieschke, K Nesic, O Kondrashova, G Ratnayake, M Radke, JS Penington, A Carmagnac, V Heong, EL Kyran, F Zhang, N Traficante, R Huang, A Dobrovic, EM Swisher, O McNally Show all

Therapeutic Advances in Medical Oncology | SAGE PUBLICATIONS LTD | Published : 2023

DOI: 10.1177/17588359231208674

Abstract

Background: Despite initial response to platinum-based chemotherapy and PARP inhibitor therapy (PARPi), nearly all recurrent high-grade serous ovarian cancer (HGSC) will acquire lethal drug resistance; indeed, ~15% of individuals have de novo platinum-refractory disease. Objectives: To determine the potential of anti-microtubule agent (AMA) therapy (paclitaxel, vinorelbine and eribulin) in platinum-resistant or refractory (PRR) HGSC by assessing response in patient-derived xenograft (PDX) models of HGSC. Design and methods: Of 13 PRR HGSC PDX, six were primary PRR, derived from chemotherapy-naïve samples (one was BRCA2 mutant) and seven were from samples obtained following chemotherapy treat..

View full abstract

University of Melbourne Researchers

Cassandra Vandenberg Author

Elizabeth Christie Author

Dale Garsed Author

Ksenija Nesic Author

Related Projects (2)

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

MOLECULAR SUBTYPE SPECIFIC THERAPY IN HIGH GRADE SEROUS OVARIAN CANCER

High grade serous ovarian cancer (HGSC) is the most common type of ovarian cancer, accounting for about two thirds of all deaths from the di..

Grants

Awarded by Eisai

Funding Acknowledgements

We thank S. Stoev, R. Hancock and K. Barber for their technical assistance. We thank Eisai Inc. for supplying eribulin; Clovis Oncology for funding Foundation Medicine sequencing of PDX; Prof Sean Grimmond and colleagues for whole genome sequencing of #198, analysis performed by Papenfuss laboratory, WEHI. This work was made possible through the Australian Cancer Research Foundation. The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Council Tasmania and The Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182) and the National Health and Medical Research Council of Australia (NHMRC; ID199600; ID400413 and ID400281). The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation. The AOCS also acknowledges the cooperation of the participating institutions in Australia and acknowledges the contribution of the study nurses, research assistants and all clinical and scientific collaborators to the study. The complete AOCS Study Group can be found at www.aocstudy.org. We would like to thank all the individuals who participated in these research programmes.